Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
864.2 DKK | -6.27% | -3.57% | +11.94% |
Feb. 27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
Feb. 14 | COLOPLAST : Q1 24: Many more positives beyond the margin beat |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 38.65 and 33.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.94% | 29.7B | B+ | ||
-33.64% | 2.9B | B- | ||
-17.23% | 2.71B | C+ | ||
+6.12% | 2.14B | - | A- | |
-1.11% | 1.91B | B | ||
-12.82% | 1.84B | - | - | |
-7.22% | 1.42B | B | ||
-2.15% | 1.26B | - | ||
+3.72% | 1.13B | - | ||
+14.59% | 1.13B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLO B Stock
- Ratings Coloplast A/S